z-logo
open-access-imgOpen Access
Prognostic Value of Chronic Kidney Disease in Acute Coronary Syndrome Patients Treated with Percutaneous Coronary Intervention
Author(s) -
Hanan Radwan,
Abdelhakem Selem,
Yaser Ammar,
Kamel Ghazal
Publication year - 2016
Publication title -
international cardiovascular forum journal
Language(s) - English
Resource type - Journals
eISSN - 2410-2636
pISSN - 2409-3424
DOI - 10.17987/icfj.v8i0.293
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , timi , mace , cardiology , myocardial infarction , acute coronary syndrome , culprit , lesion , surgery
Objective: Impact of renal impairment (RI) on short&long term outcome of percutaneous coronary intervention (PCI) in patients with ACS. Methods: 427 patients with ACS, treated with PCI .They were classified into 4 groups (normal , mild, moderate and severe renal impairment) based on creatinine clearance (eCrCl).MACE including death, new myocardial infarction (MI) and target vessel revascularization (TVR) were recorded during early (30 days) and late for average 49months. Results: Patients with severe RI had   higher number of vessels affected (p 0.023), lower grade of  TIMI flow(p0.029), lower percent dilatation of culprit lesion( p<0.001), less frequent use of GPIIb/IIIa inhibitors(p0.002) and more frequent need for TVR(p0.03). eCrCl had  positive correlation with EF and percent dilatation of  stenotic lesion (p,0.001)and   negative correlation with number of vessels & late MACE(p0.001).Patients with severe RI had increase in frequency of lateMACE compared to other groups(p0.001).TypeC lesions were more common in patients with advanced RI(p0.03).MACE free survival showed significant decline matching the decline in eCrCl among study groups. Conclusion: PCI outcome in patients with severe RI was suboptimal.They had increased riskof TVR within one month and increased riskof MI,death and total MACE on the long term.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom